The role of collateral related donors in haploidentical hematopoietic stem cell transplantation

被引:28
|
作者
Mo, Xiao-Dong [1 ]
Zhang, Yuan-Yuan [1 ]
Zhang, Xiao-Hui [1 ]
Xu, Lan-Ping [1 ]
Wang, Yu [1 ]
Yan, Chen-Hua [1 ]
Chen, Huan [1 ]
Chen, Yu-Hong [1 ]
Chang, Ying-Jun [1 ]
Liu, Kai-Yan [1 ]
Huang, Xiao-Jun [1 ,2 ,3 ]
机构
[1] Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
[2] Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
[3] Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
基金
中国国家自然科学基金;
关键词
Haploidentical; Hematopoietic stem cell transplantation; Collateral related donors; Paternal donors; Maternal donors; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; IDENTICAL-SIBLING TRANSPLANT; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC GRAFT; HEMATOLOGICAL MALIGNANCIES; UNRELATED DONORS; SINGLE-CENTER; RISK-FACTORS;
D O I
10.1016/j.scib.2018.08.008
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A key issue in the haploiedntical hematopoietic stem cell transplantation (haplo-HSCT) setting is the search for the best donor, because donor selection can significantly impact the clinical outcomes. We aimed to identify the role of collateral related donors (CRDs) in donor selection for haplo-HSCT through comparing the clinical outcomes between CRDs (n = 60) and maternal donors (MDs, n = 296), which were the last choice of donor selection in immediate related donors (IRDs). The cumulative incidence of graft-versus-host disease was comparable between CRDs and MDs. The 5-year cumulative incidence of relapse and non-relapse mortality was 22.0% (95% CI, 11.3%-32.7%) versus 17.4% (95% CI, 13.0%-21.8%) (P = 0.455) and 25.0% (95% CI, 13.9%-36.1%) versus 23.1% (95% CI, 18.2%-28.0%) (P = 0.721) for the CRDs and MDs, respectively. The 5-year probabilities of disease-free survival and overall survival was 53.2% (95% CI, 40.4%-66.0%) versus 59.5% (95% CI, 53.8%-65.2%) (P = 0.406) and 56.5% (95% CI, 43.8%-69.2%) versus 61.8% (95% CI, 56.1%-67.5%) (P = 0.458) for the CRDs and MDs, respectively. Female donor/male recipient (FDMR) CRDs were associated with the poorest clinical outcomes, and the clinical outcomes of non-FDMR CRDs were comparable to those of MDs. In summary, our results showed that CRDs did not showed superiority over MDs. Thus, IRDs should be the first choice of donor selection, and CRDs could only be the donors for those without IRDs. (C) 2018 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.
引用
收藏
页码:1376 / 1382
页数:7
相关论文
共 50 条
  • [41] Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia
    Wang, Jing-Zhi
    Huang, Xiao-Jun
    Zhang, Yuan-Yuan
    Tang, Fei-Fei
    Han, Ting-Ting
    Mo, Xiao-Dong
    Sun, Yu-Qian
    Chen, Yu-Hong
    Wang, Yu
    Zhang, Xiao-Hui
    Xu, Lan-Ping
    CHINESE MEDICAL JOURNAL, 2021, 134 (20) : 2518 - 2520
  • [42] Secondary haploidentical hematopoietic stem cell transplantation in patients with relapse or graft failure after initial hematopoietic stem cell transplantation
    Hou, Chang
    Chen, Nan
    Jiang, Shuhui
    Chen, Sifan
    Fan, Yi
    Chen, Jia
    Wang, Ying
    Xu, Yang
    Wu, Depei
    ANNALS OF HEMATOLOGY, 2019, 98 (12) : 2833 - 2836
  • [43] Secondary haploidentical hematopoietic stem cell transplantation in patients with relapse or graft failure after initial hematopoietic stem cell transplantation
    Chang Hou
    Nan Chen
    Shuhui Jiang
    Sifan Chen
    Yi Fan
    Jia Chen
    Ying Wang
    Yang Xu
    Depei Wu
    Annals of Hematology, 2019, 98 : 2833 - 2836
  • [44] Haploidentical hematopoietic stem cell transplantation in pediatric and adolescent patients: A study of the Spanish hematopoietic stem cell transplantation group (GETH)
    Ochoa-Fernandez, Barbara
    Galan-Gomez, Victor
    Mestre, Carmen
    Gonzalez-Vicent, Marta
    Pascual, Antonia
    Alonso, Laura
    Regueiro, Alexandra
    Plaza, Mercedes
    Perez Hurtado, Jose Maria
    Benito, Ana
    Luis Fuster, Jose
    Bueno, David
    Mozo, Yasmina
    Luis Vicario, Jose
    Balas, Antonio
    Sisinni, Luisa
    Diaz de Heredia, Cristina
    Perez-Martinez, Antonio
    MEDICINA CLINICA, 2022, 159 (09): : 411 - 419
  • [45] Alternative family donors for hematopoietic stem cell transplantation
    Posch, Ursula
    Ulrich, Silvia
    Schwinger, Wolfgang
    Lanzer, Gerhard
    TISSUE ANTIGENS, 2009, 73 (05): : 444 - 444
  • [46] Analysis of the Impact of KIR B Haplotype Donors on Outcomes after Haploidentical (HI) and Matched Related (MR) Hematopoietic Stem Cell Transplantation (HSCT)
    Geethakumari, Praveen Ramakrishnan
    Nair, Rasmi G.
    Grosso, Rachael
    Flomenberg, Neal
    Grosso, Dolores
    BLOOD, 2016, 128 (22)
  • [47] SUCCESSFUL SECOND HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR A CHILD WITH JUVENILE MYELOMONOCYTIC LEUKEMIA WITH GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Costa Villela, N.
    Seber, A.
    Shimoda Ikeuti, P.
    Frisanco Oliveira, A.
    de Martino Lee, M. L.
    Vasconcelos Gouveia, R.
    Vidal, D. O.
    Lopes, L. F.
    HAEMATOLOGICA, 2015, 100 : 15 - 16
  • [48] KIR genotyping of hematopoietic stem cell haploidentical donors: A single center experience
    Ingrassia, Francesco
    Pecoraro, Alice
    Blando, Maria
    Corica, Alessia Angela
    Di Paola, Floriana
    Bavetta, Rosalba
    Mistretta, Serena
    Bruno, Floriana
    Davi, Giuseppe
    Lo Brutto, Angela
    Cappuzzo, Valentina
    Fedele, Roberta
    HLA, 2023, 101 (04) : 391 - 392
  • [49] Comparison of T-cell depletion in haploidentical hematopoietic stem cell transplantation
    Marek, A.
    Stern, M.
    Chalandon, Y.
    Ansari, M.
    Guengoer, T.
    Passweg, J.
    Gratwohl, A.
    Seger, R.
    Schanz, U.
    Halter, J.
    Stussi, G.
    ONKOLOGIE, 2011, 34 : 230 - 231
  • [50] Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation
    Zhang, Ping
    Tey, Siok-Keen
    FRONTIERS IN IMMUNOLOGY, 2019, 10